Use of belatacept as alternative immunosuppression in three renal transplant patients with de novo drug-induced thrombotic microangiopathy

Case Reports in Medicine

Volumn 2013, Issue , 2013, Pages

  Cicora, Federico ^a,b   Paz, Marta ^a   Mos, Fernando ^a   Roberti, Javier ^b  

^a HOSPITAL ALEMÁN   (Argentina)

^b Foundation for Research and Assistance in Renal Disease (FINAER)   (Argentina)

Author keywords

[No Author keywords available]

Indexed keywords

BASILIXIMAB; BELATACEPT; CALCINEURIN INHIBITOR; CD28 ANTIGEN; CORTICOSTEROID; COTRIMOXAZOLE; CREATININE; EVEROLIMUS; GANCICLOVIR; MYCOPHENOLIC ACID; PREDNISONE; TACROLIMUS; THYMOCYTE ANTIBODY;

ADULT; ARTICLE; CASE REPORT; CELL ACTIVATION; CYTOMEGALOVIRUS; CYTOMEGALOVIRUS INFECTION; DEEP VEIN THROMBOSIS; DIURESIS; DRUG INDUCED DISEASE; DRUG SUBSTITUTION; DRUG WITHDRAWAL; FEMALE; HEMATOMA; HEPATITIS C; HUMAN; HUMAN PARVOVIRUS B19; HUMAN TISSUE; IMMUNOSUPPRESSIVE TREATMENT; INFECTION; KIDNEY TRANSPLANTATION; MAINTENANCE THERAPY; MALE; PARTIAL THROMBOPLASTIN TIME; PLASMAPHERESIS; POSTOPERATIVE CARE; PRIORITY JOURNAL; RECURRENT DISEASE; T LYMPHOCYTE; THROMBOCYTE COUNT; THROMBOTIC THROMBOCYTOPENIC PURPURA; URINARY TRACT FISTULA;

EID: 85030392725     PISSN: 16879627     EISSN: 16879635     Source Type: Journal    
DOI: 10.1155/2013/260254     Document Type: Article

References (16)

1. Moake J. L., Mechanisms of disease: thrombotic microangiopathies. The New England Journal of Medicine 2002 347 8 589 600 2-s2.0-0037158606 10.1056/NEJMra020528
2. Noris M., Remuzzi G., Thrombotic microangiopathy after kidney transplantation. American Journal of Transplantation 2010 10 7 1517 1523 2-s2.0-77954048044 10.1111/j.1600-6143.2010.03156.x
3. Barbour T., Johnson S., Cohney S., Hughes P., Thrombotic microangiopathy and associated renal disorders. Nephrology Dialysis Transplantation 2012 27 7 2673 2685 10.1093/ndt/gfs279
4. Satoskar A. A., Pelletier R., Adams P., Nadasdy G. M., Brodsky S., Pesavento T., Henry M., Nadasdy T., De novo thrombotic microangiopathy in renal allograft biopsies: role of antibody-mediated rejection. American Journal of Transplantation 2010 10 8 1804 1811 2-s2.0-77954901670 10.1111/j.1600-6143.2010. 03178.x
5. Øyen O., Strøm E. H., Midtvedt K., Bentdal Ø., Hartmann A., Bergan S., Pfeffer P., Brekke I. B., Calcineurin inhibitor-free immunosuppression in renal allograft recipients with thrombotic microangiopathy/hemolytic uremic syndrome. American Journal of Transplantation 2006 6 2 412 418 2-s2.0-33644914494 10.1111/j.1600-6143.2005.01184.x (Pubitemid 43382180)
6. Karthikeyan V., Parasuraman R., Shah V., Vera E., Venkat K. K., Outcome of plasma exchange therapy in thrombotic microangiopathy after renal transplantation. American Journal of Transplantation 2003 3 10 1289 1294 2-s2.0-0141781175 10.1046/j.1600-6143.2003.00222.x (Pubitemid 37214626)
7. Hadaya K., Ferrari-Lacraz S., Fumeaux D., Boehlen F., Toso C., Moll S., Martin P.-Y., Villard J., Eculizumab in acute recurrence of thrombotic microangiopathy after renal transplantation. American Journal of Transplantation 2011 11 11 2523 2527 2-s2.0-84857190406 10.1111/j.1600-6143.2011.03696.x
8. Clark W. F., Thrombotic microangiopathy: current knowledge and outcomes with plasma exchange. Seminars in Dialysis 2012 25 2 214 219 2-s2.0-84858705735 10.1111/j.1525-139X.2011.01035.x
9. Sartelet H., Toupance O., Lorenzato M., Fadel F., Noel L. H., Lagonotte E., Birembaut P., Chanard J., Rieu P., Sirolimus-induced thrombotic microangiopathy is associated with decreased expression of vascular endothelial growth factor in kidneys. American Journal of Transplantation 2005 5 10 2441 2447 2-s2.0-33644685230 10.1111/j.1600-6143.2005.01047.x
10. Campistol J. M., Arias M., Ariceta G., An update for atypical haemolytic uraemic syndrome: diagnosis and treatment. A consensus document. Nefrologia 2013 33 1 27 45
11. Grinyó J. M., Budde K., Citterio F., Charpentier B., Belatacept utilization recommendations: an expert position. Expert Opinion on Drug Safety 2013 12 1 111 122 10.1517/14740338.2013.748747
12. Charpentier B., Belatacept: a novel immunosuppressive agent for kidney transplant recipients. Expert Review of Clinical Immunology 2012 8 8 719 728 10.1586/eci.12.79
13. Dierkes F., Andriopoulos N., Sucker C., Kuhr K., Hollenbeck M., Hetzel G. R., Burst V., Teschner S., Rump L. C., Benzing T., Grabensee B., Kurschat C. E., Indicators of acute and persistent renal damage in adult thrombotic microangiopathy. PLoS ONE 2012 7 1 2-s2.0-84856080487 10.1371/journal.pone. 0030886 e30886
14. Fortin M.-C., Raymond M. A., Madore F., Increased risk of thrombotic microangiopathy in patients receiving a cyclosporin-sirolimus combination. American Journal of Transplantation 2004 4 6 946 952 10.1111/j.1600-6143.2004. 00428.x (Pubitemid 38745594)
15. Saikali J. A., Truong L. D., Suki W. N., Sirolimus may promote thrombotic microangiopathy. American Journal of Transplantation 2003 3 2 229 230 2-s2.0-0037297156 10.1034/j.1600-6143.2003.00018.x (Pubitemid 36323121)
16. Archdeacon P., Dixon C., Belen O., Albrecht R., Meyer J., Summary of the US FDA approval of belatacept. American Journal of Transplantation 2012 12 3 554 562 2-s2.0-84857659576 10.1111/j.1600-6143.2011.03976.x